NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 1 to 25 of 1245

Display Results as:

Cooperative Agreement to Support Regulatory Research Related to the 2018 Prescription Drug User Fee Act and the 21st Century Cures Act - RFA-FD-18-013

Organization: FDA 

Posting Date: 04-24-2018 

Expiration Date: 06-26-2018 

Activity Code: U19 

Summary: The primary objective of this effort is to provide supporting research, identify key issues, and convene appropriate subject matter experts to help inform major initiatives for process improvement and regulatory science related to FDA commitments under the 2018 reauthorization of the Prescription Drug User Fee Act (PDUFA VI) and the 21st Century Cures Act legislation. 

NIH Director's Pioneer Award (DP1 - Clinical Trial Optional) - RFA-RM-18-007

Organization: RMOD 

Posting Date: 04-23-2018 

Expiration Date: 09-15-2018 

Activity Code: DP1 

Summary: The NIH Directors Pioneer Award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative approaches to major challenges in the biomedical or behavioral sciences towards the goal of enhancing human health. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. 

Targeted In Vivo Delivery of Gene Therapeutics for HIV Cure (R01 Clinical Trial Not Allowed) - RFA-AI-18-016

Organization: NIAID 

Posting Date: 04-20-2018 

Expiration Date: 08-01-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) will support research on the development and validation of innovative strategies to deliver anti-HIV gene therapies efficiently to specific target cells in vivo. 

Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional) - PAR-18-764

Organization: NIAID 

Posting Date: 04-20-2018 

Expiration Date: 05-08-2021 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. 

Cooperative Agreement to Support the Food and Agriculture Organization (FAO) (U01) - RFA-FD-18-009

Organization: FDA 

Posting Date: 04-20-2018 

Expiration Date: 07-03-2018 

Activity Code: U01 

Summary: The Food and Drug Administration (FDA) is announcing its intention to receive and consider a single source application for award of a cooperative agreement in fiscal year 2018 (FY 2018) to the Food and Agriculture Organization (FAO) of the United Nations to support global strategies that address food safety, nutrition and public health. The purpose of this cooperative agreement is to: 1. Utilize FAO's extensive research and expertise on country development and aid activities. 2. Contribute to the research, knowledge base and development of food safety systems globally due to the increasingly diverse and complex food supply. 3. Enhance and broaden FDA's ability to address global food safety, nutrition, and public health issues associated with food. 4. Provide opportunities to leverage additional resources of other countries. 5. Support the FDA Food Safety Modernization Act (FSMA) and FDA's International Food Safety Capacity Building Plan, which emphasizes the concept of preventing food safety-related problems before they occur and the importance of establishing strong relationships and mutual support among all stakeholders, including multilateral organizations, to improve worldwide food safety. 6. Support food safety, nutrition and public health programs that align with FDA's mission. 

Enhancing Innovations in Emerging Technologies for Advanced Manufacturing of Complex Biologic Products (R01) - RFA-FD-18-023

Organization: FDA 

Posting Date: 04-20-2018 

Expiration Date: 06-26-2018 

Activity Code: R01 

Summary: CBER seeks to support the application of novel technologies for advanced manufacturing of complex biologic products, and innovative analytical approaches to improve product manufacturing and quality through active research. 

BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed) - RFA-NS-18-030

Organization: NINDS 

Posting Date: 04-19-2018 

Expiration Date: 11-11-2020 

Activity Code: R01 

Summary: This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human and human species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior. 

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) - PAR-18-763

Organization: NINDS 

Posting Date: 04-19-2018 

Expiration Date: 05-08-2021 

Activity Code: R61/R33 

Summary: This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery. 

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) - PAR-18-761

Organization: NINDS 

Posting Date: 04-19-2018 

Expiration Date: 05-08-2021 

Activity Code: R61/R33 

Summary: This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs. 

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) - PAR-18-762

Organization: NINDS 

Posting Date: 04-19-2018 

Expiration Date: 05-08-2021 

Activity Code: R61/R33 

Summary: This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. 

Limited Competition: Interaction of HIV Infection and Alcohol Abuse on Central Nervous System Morbidity (U01 Clinical Trial Not Allowed) - RFA-AA-18-011

Organization: NIAAA 

Posting Date: 04-19-2018 

Expiration Date: 07-04-2018 

Activity Code: U01 

Summary: The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to evaluate the cumulative and progressive effects on brain structure and cognitive/behavioral function of combined HIV infection and alcohol abuse on older patients cohorts. 

Summer Institute for Research Education in Biostatistics (R25 - Clinical Trials Not Allowed) - RFA-HL-19-019

Organization: NHLBI 

Posting Date: 04-18-2018 

Expiration Date: 06-29-2018 

Activity Code: R25 

Summary: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHLBI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development 

In Vivo Synaptic Function in Alzheimers Disease and Related Dementias (R21 Clinical Trial Not Allowed) - PAR-18-760

Organization: NIA 

Posting Date: 04-18-2018 

Expiration Date: 01-08-2021 

Activity Code: R21 

Summary: To study in vivo synaptic structure and function in Alzheimer's and related dementia; and to advance development of methods to study synapses in animal models and humans. 

Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed) - RFA-HG-18-002

Organization: NHGRI 

Posting Date: 04-18-2018 

Expiration Date: 09-11-2020 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than an order of magnitude) improvement in DNA sequencing, and practical methods for direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA. 

Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed) - RFA-HG-18-001

Organization: NHGRI 

Posting Date: 04-18-2018 

Expiration Date: 09-11-2020 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable no less than one order of magnitude improvement in DNA sequencing, and practical methods for direct RNA sequencing. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained DNA sequencing throughput increases and cost decreases. The goal now is to improve the quality and efficiency of DNA sequencing and enable direct RNA sequencing (e.g., longer read lengths, faster turn-around time, greater accuracy, and higher-throughput etc.) at reasonable costs with the anticipation that significant advances in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRIs other technology development goals. 

Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed) - RFA-HG-18-003

Organization: NHGRI 

Posting Date: 04-18-2018 

Expiration Date: 09-11-2020 

Activity Code: R43/R44 

Summary: This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications from small businesses to develop novel technologies that will enable no less than one order of magnitude improvement in DNA sequencing, and practical methods for direct RNA sequencing. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained DNA sequencing throughput increases and cost decreases. The goal now is to improve the quality and efficiency of DNA sequencing and enable direct RNA sequencing (e.g., longer read lengths, faster turn-around time, greater accuracy, and higher-throughput etc.) at reasonable costs with the anticipation that significant advances in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRIs other technology development goals. 

Administrative Supplements to NIGMS Predoctoral Training Grants for the Development of Activities to Prepare Trainees for Careers in the Biomedical Research Workforce (Admin Supp Clinical Trial Not Allowed) - PA-18-757

Organization: NIGMS 

Posting Date: 04-17-2018 

Expiration Date: 05-19-2018 

Activity Code: (Admin Supp) 

Summary: The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of activities aimed at broadening the training experience to better prepare individuals for careers in the biomedical research workforce.). 

Development of Curricular or Training Activities in Rigor and Transparency to Enhance Reproducibility (Admin Supp Clinical Trial Not Allowed) - PA-18-756

Organization: NIGMS 

Posting Date: 04-17-2018 

Expiration Date: 05-19-2018 

Activity Code: (Admin Supp) 

Summary: The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of curricular or training activities aimed at providing graduate trainees with a strong foundation in areas related to conducting rigorous and transparent research to enhance reproducibility in the biomedical sciences. 

Development of Curricular or Training Activities in Laboratory Safety (Admin Supp Clinical Trial Not Allowed) - PA-18-758

Organization: NIGMS 

Posting Date: 04-17-2018 

Expiration Date: 05-19-2018 

Activity Code: (Admin Supp) 

Summary: The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of curricular or training activities aimed at providing trainees with the knowledge and skills to enhance laboratory safety. The funds are designed to promote the reworking and revitalization of biomedical predoctoral research education and training. 

Development of Curricular or Training Activities in Skills Development (Admin Supp Clinical Trial Not Allowed) - PA-18-759

Organization: NIGMS 

Posting Date: 04-17-2018 

Expiration Date: 05-19-2018 

Activity Code: (Admin Supp) 

Summary: The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of curricular or training activities aimed at the development of the technical, operational, or professional skills to become a biomedical scientist. The funds are designed to promote the reworking and revitalization of biomedical predoctoral research education and training. 

Development of a virtual bioequivalence trial simulation platform that integrates population pharmacokinetic modeling algorithms into physiologically-based pharmacokinetic models (U01) - RFA-FD-18-018

Organization: FDA 

Posting Date: 04-11-2018 

Expiration Date: 06-21-2018 

Activity Code: U01 

Summary: The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development. 

NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials) - PAR-18-755

Organization: NIMH 

Posting Date: 04-11-2018 

Expiration Date: 05-08-2021 

Activity Code: K22 

Summary: The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (DIRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields 

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed) - PAR-18-752

Organization: NCI 

Posting Date: 04-11-2018 

Expiration Date: 07-01-2018 

Activity Code: (Admin Supp) 

Summary: This administrative supplement funding opportunity announcement (FOA) from the National Cancer Institute (NCI) is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents. The DRSN was also developed to assist in issues of cancer drug resistance in the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical industry partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-U54 investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials. 

Geriatrics and Clinical Gerontology Research to Address Health Disparities in the U.S. (Admin Supp Clinical Trial Not Allowed) - PA-18-751

Organization: NIA 

Posting Date: 04-11-2018 

Expiration Date: 07-17-2018 

Activity Code: (Admin Supp) 

Summary: This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support aging research that addresses disparities in health, with emphasis on geriatrics and clinical gerontology studies. 

Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01 Clinical Trial Optional) - PA-18-753

Organization: NIAID 

Posting Date: 04-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

RMOD

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top